pillarbiosc

Four people smile out of the screen from their lab stations.

The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories

Increasingly, clinical samples of all types are being analyzed with the goal of matching patients to target therapies. In the summer of 2017, Thermo Fisher received the first FDA companion diagnostic test approval for multiple non-small cell lung cancer (NSCLC) therapies, while Foundation Medicine received FDA approval for their FoundationFocus CDxBRCA as a companion diagnostic for an ovarian cancer …

The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories Read More »

Pillar NGS panels go global with increased platform versatility

Pillar Biosciences, an NGS diagnostics company based in Boston, MA, announced today that Pillar® ONCO/Reveal™ NGS panels are now compatible with Illumina®, Ion Torrent™, and MGI™ sequencing platforms. Additionally, Pillar has entered into a co-marketing agreement with MGI that will highlight the compatibility between Pillar’s NGS assays and MGI’s sequencing platform-agnostic sample prep robotics. “With …

Pillar NGS panels go global with increased platform versatility Read More »

Greater versatility with Pillar Biosciences. Social media graphic advertising that Pillar will be at AMP 2019. Background image is a boat moored in front of the Baltimore, Maryland skyline

Join Pillar at AMP 2019

Event date: November 6-9, 2019 Location: Baltimore, Maryland, USA Join Pillar Biosciences at the Association for Molecular Pathology’s Annual Meeting and Expo 2019 where we will showcase Pillar® NGS assays, which provide versatility across platforms, mutation types and panel designs. Corporate Workshop Come listen to Cynthia Schandl, MD, PhD and Julie Hirschhorn, PhD of the …

Join Pillar at AMP 2019 Read More »

Top 5 reasons to go custom with Pillar Biosciences in graphic font

5 reasons to go custom with your next sequencing panel

Off-the-shelf next-generation sequencing (NGS) panels save on sequencing costs by targeting specific genes, and the smaller resulting datasets are easier to analyze. The catch is, panels are limited to a defined set of genetic targets. This one-size-fits all approach is not well-suited to the cancer research community’s rapid pace of discovery. Custom panels, on the …

5 reasons to go custom with your next sequencing panel Read More »

Helen Fernandes at Columbia University uses Pillar NGS panel as new tumor sequencing workhorse

Meet SLIMamp: Columbia University’s new tumor sequencing workhorse

Next generation sequencing (NGS) is a powerful diagnostic tool for identifying tumor variants. Tumor sequencing workflows often rely on off-the-shelf panels, which allow for multiplexed amplification of known cancer mutational “hotspots”. These panels are diagnostically useful, but they can’t keep pace with the cancer research community’s diligent uncovering of new, previously unknown hotspots, genes, and …

Meet SLIMamp: Columbia University’s new tumor sequencing workhorse Read More »

Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel

BOSTON, May 30, 2019 /PRNewswire/ — Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today that the Columbia Solid Tumor Panel, a next-generation sequencing (NGS) panel, received conditional approval by the New York State Department of Health for clinical use by the Laboratory of Personalized Genomic Medicine at Columbia University Medical …

Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel Read More »

Pillar Biosciences Enters Strategic Partnership With China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

SAN FRANCISCO, CA, Jan. 10, 2019 /PRNEWSWIRE/ – Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA and Shanghai, China, is forming a strategic partnership and joint venture with China Biotech Services Holdings, Ltd (CBSH; HKSE:08037). The agreement was signed on January 9th at the JP Morgan Healthcare Conference in San Francisco. …

Pillar Biosciences Enters Strategic Partnership With China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia Read More »

Pillar Biosciences Announces Issuance of China and U.S. Patents Covering SLIMamp™ Technology

NATICK MASSACHUSETTS, Dec. 11, 2017 /PRNEWSWIRE/ – Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces that key patents covering its SLIMamp™ technology have been issued in its most important markets China and the United States. The State Intellectual Property Office (SIPO) of …

Pillar Biosciences Announces Issuance of China and U.S. Patents Covering SLIMamp™ Technology Read More »

Pillar Biosciences announces ISO 13485:2016 Certification

NATICK MASSACHUSETTS, Nov. 29, 2017 /PRNEWSWIRE/ – Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces it has received ISO 13485:2016 certification for design, development, manufacture, and distribution of products for the clinical oncology laboratory within a comprehensive quality management system (QMS). The …

Pillar Biosciences announces ISO 13485:2016 Certification Read More »

Scroll to Top